Photo by nci from unsplash
People living with human immunodeficiency virus (PLHIV) are at increased risk of cardiovascular disease due to metabolic abnormalities, chronic inflammation and immune dysregulation. PLHIV may receive suboptimal lipid-lowering therapy because… Click to show full abstract
People living with human immunodeficiency virus (PLHIV) are at increased risk of cardiovascular disease due to metabolic abnormalities, chronic inflammation and immune dysregulation. PLHIV may receive suboptimal lipid-lowering therapy because of drug-drug interactions between high-intensity statins
Keywords:
evolocumab use;
human immunodeficiency;
use patients;
immunodeficiency virus
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!